Analysts See $-0.13 EPS for Insulet (PODD); Morgan Stanley Emerging Markets Fund Has 1.88 Sentiment

July 17, 2017 - By Hazel Jackson

The Morgan Stanley Emerging Markets Fund, Inc. is a diversified, closed-end management investment company. The company has market cap of $240.93 million. The Fund’s investment objective is long-term capital appreciation through investments primarily in emerging country equity securities. It currently has negative earnings. It invests in various sectors, such as banks; insurance; diversified telecommunication services; food and staples retailing; food products; Internet software and services; oil, gas and consumable fuels; automobiles; beverages; construction and engineering; hotels, restaurants and leisure; independent power producers and energy traders; Internet and catalog retail; machinery; pharmaceuticals, real estate management and development; textiles, apparel and luxury goods; transportation infrastructure, and wireless telecommunication services.

Analysts expect Insulet Corporation (NASDAQ:PODD) to report $-0.13 EPS on August, 3 after the close.They anticipate $0.05 EPS change or 62.50% from last quarter’s $-0.08 EPS. After having $-0.17 EPS previously, Insulet Corporation’s analysts see -23.53% EPS growth. About 240,990 shares traded. Insulet Corporation (NASDAQ:PODD) has risen 48.83% since July 17, 2016 and is uptrending. It has outperformed by 32.13% the S&P500.

Since March 2, 2017, it had 3 insider purchases, and 4 insider sales for $3.48 million activity. Thomas Bradley A had bought 3,000 shares worth $116,077. 1,524 shares were sold by Lemoine David A, worth $66,142 on Monday, May 1. On Tuesday, May 16 Spears Michael P bought $101,470 worth of Insulet Corporation (NASDAQ:PODD) or 2,500 shares. Hopfield Jessica also bought $99,783 worth of Insulet Corporation (NASDAQ:PODD) on Thursday, May 11. Zakrzewski Joseph S sold $1.87 million worth of Insulet Corporation (NASDAQ:PODD) on Thursday, March 2. SOMMER REGINA O sold 40,000 shares worth $1.80M.

Insulet Corporation is engaged in the development, manufacturing and sale of the OmniPod Insulin Management System , an insulin delivery system for people with insulin-dependent diabetes. The company has market cap of $2.94 billion. The Omnipod System features a self-adhesive disposable tubeless Omnipod device, which is worn on the body for approximately three days at a time and its wireless companion, the handheld Personal Diabetes Manager (PDM). It currently has negative earnings. The Omnipod System features two discreet devices that eliminate the need for a bulky pump, tubing and separate blood glucose meter, provides for virtually pain-free automated cannula insertion, communicates wirelessly and integrates a blood glucose meter.

Investors sentiment decreased to 0.87 in Q4 2016. Its down 0.25, from 1.12 in 2016Q3. It turned negative, as 26 investors sold Insulet Corporation shares while 58 reduced holdings. 21 funds opened positions while 52 raised stakes. 60.26 million shares or 0.42% more from 60.00 million shares in 2016Q3 were reported. Axa owns 134,078 shares or 0.02% of their US portfolio. Bankshares Of Ny Mellon Corporation holds 0% of its portfolio in Insulet Corporation (NASDAQ:PODD) for 269,851 shares. Barclays Pcl has 4,012 shares. Guggenheim Capital Limited Liability Company has 0% invested in Insulet Corporation (NASDAQ:PODD) for 7,056 shares. Fiera Capital owns 165,285 shares. Moreover, Great West Life Assurance Can has 0% invested in Insulet Corporation (NASDAQ:PODD) for 5,535 shares. Panagora Asset Mgmt has 26,399 shares. Goldman Sachs holds 0% in Insulet Corporation (NASDAQ:PODD) or 242,872 shares. Morgan Stanley stated it has 0.01% of its portfolio in Insulet Corporation (NASDAQ:PODD). Champlain Invest Ptnrs Limited Liability Company holds 957,245 shares. 37,250 were accumulated by Moreno Evelyn V. Old National Bank In owns 6,540 shares. 9,266 were reported by Proshare Ltd Llc. American Group Inc accumulated 33,175 shares. Valinor L P has invested 2.62% in Insulet Corporation (NASDAQ:PODD).

Among 10 analysts covering Insulet Corporation (NASDAQ:PODD), 6 have Buy rating, 1 Sell and 3 Hold. Therefore 60% are positive. Insulet Corporation had 21 analyst reports since July 29, 2015 according to SRatingsIntel. The stock has “Outperform” rating by William Blair on Friday, April 29. On Friday, January 6 the stock rating was upgraded by Robert W. Baird to “Outperform”. On Thursday, February 25 the stock rating was initiated by Empire with “Sell”. The firm has “Hold” rating by Benchmark given on Thursday, August 13. The stock has “Equal-Weight” rating by Morgan Stanley on Monday, November 2. The stock has “Outperform” rating by Wedbush on Tuesday, February 28. The stock of Insulet Corporation (NASDAQ:PODD) has “Buy” rating given on Thursday, August 4 by Jefferies. The stock of Insulet Corporation (NASDAQ:PODD) earned “Outperform” rating by Northland Capital on Friday, November 6. Benchmark upgraded Insulet Corporation (NASDAQ:PODD) on Friday, February 26 to “Buy” rating. Jefferies maintained the shares of PODD in report on Thursday, July 13 with “Buy” rating.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: